Skip to main content

ADVERTISEMENT

clinical pathways

Supporting Optimal, Value-Based, and Sustainable Cancer Care Delivery
Perspectives
10/21/2020
Barbara McAneny, MD
Lee Schwartzberg, MD, FACP
Wui-Jin Koh, MD
Edward Arrowsmith, MD
Alison Fugaro, PA
Tyler Haydell
Paul J Hesketh, MD
Anita Pudusseri, DO
Sylvia Richey, MD
Corrine Zarwan, MD
Rebecca Stein
Abstract: As the cancer care landscape continues to evolve, oncologists must stay up to date on the latest treatment options for their patients while also navigating the administrative complexities of running a...
Abstract: As the cancer care landscape continues to evolve, oncologists must stay up to date on the latest treatment options for their patients while also navigating the administrative complexities of running a...
...
10/21/2020
Journal of Clinical Pathways
Developing Pathway to Cure: A Multimodal Clinical Pathway Platform to Support Timely and Appropriate Care of Women Under 50 Diagnosed With Breast Cancer
From the Field
09/18/2020
Robin M Lally, PhD, MS, RN, AOCN, FAAN1,2
Roksana Zak, PhD1
Ryan Ramaekers, MD3
Allison F Coates, BS, BSN, RN1
Elizabeth Reed, MD2
Abstract: Pathway to Cure is a multimodal eHealth platform for oncology care providers and patients developed by a multidisciplinary team at the University of Nebraska Medical Center’s Fred & Pamela Buffett...
Abstract: Pathway to Cure is a multimodal eHealth platform for oncology care providers and patients developed by a multidisciplinary team at the University of Nebraska Medical Center’s Fred & Pamela Buffett...
...
09/18/2020
Journal of Clinical Pathways
Elsevier’s ClinicalPath: Supporting Value-Based Care and the Path Forward
Interview
07/07/2020
In January 2018, Elsevier—an information analytics business specializing in science and health—acquired Via Oncology – a leading decision-support and clinical pathways vendor. Since that time, Elsevier has rebranded...
In January 2018, Elsevier—an information analytics business specializing in science and health—acquired Via Oncology – a leading decision-support and clinical pathways vendor. Since that time, Elsevier has rebranded...
In...
07/07/2020
Journal of Clinical Pathways
Identifying and Addressing Multi-Stakeholder Gaps in Value Assessment
Interview
06/12/2020
While there is general consensus that existing value assessment methods are imperfect solutions for providing credible and relevant information on value specific to cancer care decisions, there is much less consensus...
While there is general consensus that existing value assessment methods are imperfect solutions for providing credible and relevant information on value specific to cancer care decisions, there is much less consensus...
While...
06/12/2020
Journal of Clinical Pathways
Prior Authorization for Comprehensive Genomic Profiling in Clinical Pathways
Interview
05/27/2020
At the Community Oncology Alliance (COA) Annual Meeting (April 24, 2020), Lee Schwartzberg, MD, FACP, West Cancer Center and Research Institute (a member of OneOncology), moderated a stakeholder panel discussion on...
At the Community Oncology Alliance (COA) Annual Meeting (April 24, 2020), Lee Schwartzberg, MD, FACP, West Cancer Center and Research Institute (a member of OneOncology), moderated a stakeholder panel discussion on...
At the...
05/27/2020
Journal of Clinical Pathways
News
05/20/2020
An infographic published in JCO Oncology Practice (online May 12, 2020; doi:10.1200/OP.20.00179) highlights updates to the American Society of Clinical Oncology (ASCO) Patient-Centered Oncology Payment (PCOP)...
An infographic published in JCO Oncology Practice (online May 12, 2020; doi:10.1200/OP.20.00179) highlights updates to the American Society of Clinical Oncology (ASCO) Patient-Centered Oncology Payment (PCOP)...
An...
05/20/2020
Journal of Clinical Pathways
The Challenge of Developing Pathways in a Rapidly Evolving Clinical Space: Chronic Lymphocytic Leukemia as a Case Study
Perspectives
03/16/2020
Andrew Hertler, MD, FACP
William A Flood, MD, MS
Ray Page, DO, PhD, FACOI, FASCO
Barry Brooks, MD
Steve L D’Amato, BSPharm, BCOP
Michael Kolodziej, MD
Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...
Abstract: Clinical pathways represent an effort to optimize value-based clinical decision making by standardizing (when appropriate) evidence-based care to offer patients the best outcome while remaining mindful of...
...
03/16/2020
Journal of Clinical Pathways
From the Field
05/15/2019
Christopher Koprowski, MD, MBA
Nicholas Petrelli, MD, FACS
Edith J Johnson, PhD, MBA
Karen Sites, MSN, RN, OCN
Abstract: It was hypothesized that by introducing more intense supportive care and enhanced nurse navigation in high-acuity curable cancer patients, we could achieve the same results noted in patients with advanced...
Abstract: It was hypothesized that by introducing more intense supportive care and enhanced nurse navigation in high-acuity curable cancer patients, we could achieve the same results noted in patients with advanced...
...
05/15/2019
Journal of Clinical Pathways
Research Reports
02/15/2018
Casey Mason
Peter G Ellis, MD
Kathy Lokay
Amanda Barry, MPH
Natalie Dickson, MD
Ray Page, DO, PhD
Blase Polite, MD
Ravi Salgia, MD, PhD
Michael Savin, MD
Corey Shamah, MD
Mark A Socinski, MD
Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...
Abstract: Despite clear clinical benefit and guideline recommendations for predictive biomarker testing and subsequent first-line targeted therapy treatment in patients with non–small cell lung cancer (NSCLC), there...
...
02/15/2018
Journal of Clinical Pathways
Research Reports
10/16/2017
Chadi Nabhan, MD, MBA, FACP
Yolaine Jeune-Smith, PhD
Peter Klinefelter, BA
Jennifer Fillman, MBA
Bruce A. Feinberg, DO
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
Abstract: The Oncologic Drugs Advisory Committee recently voted 10-0 recommending to the Food and Drug Administration (FDA) the approval of the first chimeric antigen receptor T (CAR-T) therapy. We sought to better...
...
10/16/2017
Journal of Clinical Pathways